NVCT Logo

Nuvectis Pharma, Inc. (NVCT) 

NASDAQ
Market Cap
$90.04M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
196 of 960
Rank in Industry
128 of 550

Largest Insider Buys in Sector

NVCT Stock Price History Chart

NVCT Stock Performance

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Insider Activity of Nuvectis Pharma, Inc.

Over the last 12 months, insiders at Nuvectis Pharma, Inc. have bought $424,826 and sold $22,478 worth of Nuvectis Pharma, Inc. stock.

On average, over the past 5 years, insiders at Nuvectis Pharma, Inc. have bought $2.53M and sold $22,478 worth of stock each year.

Highest buying activity among insiders over the last 12 months: BENTSUR RON (Chairman & CEO) — $527,177. Mosseri Marlio Charles (10 percent owner) — $228,941. Poradosu Enrique (Chief Science & Business Off) — $13,125.

The last purchase of 17,000 shares for transaction amount of $79,900 was made by Mosseri Marlio Charles (10 percent owner) on 2024‑12‑13.

List of Insider Buy and Sell Transactions, Nuvectis Pharma, Inc.

2024-12-13Purchase10 percent owner
17,000
0.0872%
$4.70$79,900+3.62%
2024-12-12Purchase10 percent owner
32,121
0.1662%
$4.64$149,041+3.13%
2024-11-19PurchaseChief Science & Business Off
2,000
0.0103%
$4.99$9,980+1.20%
2024-11-15PurchaseChairman & CEO
20,000
0.0887%
$4.92$98,400-0.81%
2024-11-07SaleVice President, Finance
2,755
0.0146%
$8.16$22,478-40.65%
2024-05-14PurchaseChairman & CEO
1,940
0.0105%
$6.74$13,076-3.40%
2024-05-10PurchaseChairman & CEO
2,000
0.0109%
$6.40$12,800+2.03%
2024-05-10PurchaseChief Science & Business Off
500
0.0027%
$6.29$3,145+2.03%
2024-05-10PurchaseChief Dev. & Ops. Officer
1,113
0.006%
$6.32$7,034+2.03%
2024-03-18PurchaseChairman & CEO
5,000
0.0283%
$10.29$51,450-36.51%
2023-10-10PurchaseChairman & CEO
640
0.0038%
$11.08$7,091-31.90%
2023-10-09PurchaseChairman & CEO
830
0.0049%
$11.19$9,288-32.61%
2023-10-06PurchaseChairman & CEO
250
0.0014%
$11.27$2,818-34.47%
2023-10-05PurchaseChairman & CEO
1,400
0.0076%
$11.09$15,526-31.83%
2023-10-04PurchaseChairman & CEO
1,820
0.0098%
$10.95$19,929-32.59%
2023-08-16PurchaseChairman & CEO
115
0.0008%
$15.15$1,742-42.41%
2023-08-15PurchaseChairman & CEO
235
0.0015%
$14.34$3,370-41.99%
2023-08-11PurchaseChairman & CEO
180
0.0011%
$14.66$2,639-46.24%
2023-08-08PurchaseChairman & CEO
120
0.0008%
$14.83$1,780-44.32%
2023-07-31Purchase10 percent owner
860
0.0058%
$13.88$11,937-41.05%

Insider Historical Profitability

1.65%
BENTSUR RONChairman & CEO
3266424
16.9061%
$4.66540+8.4%
Mosseri Marlio Charles10 percent owner
2644121
13.6852%
$4.66210<0.0001%
Poradosu EnriqueChief Science & Business Off
1506319
7.7963%
$4.6660+25.81%
Shemesh ShayChief Dev. & Ops. Officer
1493068
7.7277%
$4.66130+27.08%
Hoberman Kenneth
55140
0.2854%
$4.6610<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$3.06M2.03372,721-3.91%-$124,394.03<0.0001
The Vanguard Group$2.45M1.63298,800+1.53%+$37,039.39<0.0001
Baldwin Brothers Inc Ma$1.26M0.84154,130+8.51%+$99,138.000.1
Geode Capital Management$1.1M0.73134,528+2.18%+$23,544.11<0.0001
State Street$1.06M0.71129,379+9.38%+$91,020.02<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.